News

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.

Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...

In a post on LinkedIn on Monday, Angelos Stergiou said despite speculation and outside commentary ‘naturally’ increasing, the company will let the data speak for itself.

Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]

On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.

SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results showing a net loss of US$9.61 million and basic loss per share from continuing operations of US$0.05, with first-half 2026 net loss reaching US$18.01 million and basic loss per share of US$0.10. Despite wider net losses in dollar terms, the company’s loss per share narrowed year on year, pointing to the impact of share count changes amid heightened interest in its Phase 3 GPS cancer vaccine program following positive...

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

SELLAS Life Sciences Group stock has posted a very large 3 year return while the latest valuation checks flag it as expensive rather than a clear bargain. Over the past 3 years, SELLAS Life Sciences Group has delivered a gain of about 7.9x, which sets a high bar for any further upside to be justified. Progress toward key milestones in the REGAL AML trial and the advancement of SLS009 in difficult cancer indications can support high growth expectations, yet the usual risks around clinical...

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis and held an estimated US$138.30 million in cash at the end of June. This combination of an imminent pivotal trial readout and a strengthened institutional presence highlights how clinical and balance-sheet milestones are converging for...

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

Earlier this week, SELLAS Life Sciences Group highlighted that its REGAL Phase 3 trial of galinpepimut-S (GPS) in acute myeloid leukemia has reached 78 of the 80 required overall survival events, bringing the pivotal data readout within sight. Investor interest has also been shaped by amended executive employment agreements that include change-of-control benefits, feeding speculation about potential corporate developments alongside the awaited GPS results. With the REGAL Phase 3 GPS data...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet the stock currently screens as expensive on broad valuation checks. This sets up a clear tension between recent share price strength and what the fundamentals suggest about value. Over 3 years, the stock has returned close to 7x, which puts extra focus on whether that gain is supported by fundamentals or mainly by sentiment. Expectations for strong revenue and earnings growth, combined with a sizeable shelf registration...

SELLAS Life Sciences Group (SLS) is drawing focused attention as its Phase 3 trial for galinpepimut-S in acute myeloid leukemia approaches the required events for an overall survival readout, a key catalyst for the stock. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.19, SELLAS Life Sciences Group has seen a 69.97% 1 month share price return and a 203.22% year to date share price return. The 1 year total shareholder return is very large, signaling that...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is one of the 10 Best Performing American Stocks in June 2026. On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm […]

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

SELLAS Life Sciences Group stock has surged over the past three years, yet its low overall value score and rich market multiples leave investors weighing a strong price run against signals that the shares may already be pricing in a lot of good news. A roughly 8.5x return over 3 years places SELLAS Life Sciences Group among the stronger movers in biotech, which can heighten the risk that expectations get ahead of fundamentals. Anticipation around the Phase 3 REGAL AML trial readout and...

In recent days, SELLAS Life Sciences Group updated employment and severance agreements for key executives while its Phase 3 REGAL trial in acute myeloid leukemia neared final overall survival analysis, with 78 of 80 required events reached. These enhanced change‑of‑control terms, combined with the late‑stage status of galinpepimut‑S and early‑stage CDK9 inhibitor SLS009, have intensified market discussion about potential acquisition interest and the company’s long‑term oncology...

We just covered the 10 Stocks That Will 10X According to Social Media. Sellas Life Sciences (NASDAQ:SLS) ranks #10 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 13 Sellas Life Sciences (NASDAQ:SLS) is one of the top favorite stocks social media believes can 10x. It is a biotech […]

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated: Oh, this life science company that is, look, okay, so this is […]

In recent days, SELLAS Life Sciences Group drew attention as its CEO highlighted real-world data and prior Phase 2 results while the Phase 3 REGAL trial of GPS in AML moved to within two events of a topline readout. Investor interest was further amplified when CNBC’s Jim Cramer described SELLAS as “a great spec,” underscoring how imminent REGAL data and the progress of second AML candidate SLS009 are shaping perceptions of the company’s pipeline. We’ll now examine how the approaching REGAL...

Earlier in 2026, SELLAS Life Sciences Group, Inc. reported a US$8.41 million net loss for the first quarter but narrowed its basic loss per share to US$0.05, while confirming that its pivotal Phase 3 REGAL trial in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis. At the same time, SELLAS advanced its SLS009 program into an 80‑patient Phase 2 trial for newly diagnosed, high‑risk acute myeloid leukemia and secured additional funding flexibility through a...

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline. CEO Angelos Stergiou said the company continued advancing its clinical programs during the quarter while preparing for the anticipated data readout from its pivotal Phase 3 REGAL study. SELLAS will release the upcoming data after the study reaches its pre-specified 80th event threshold — a major milestone for the

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is […]

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]